# Safety Study of Infusion of SGT-53 to Treat Solid Tumors

> **NCT00470613** · PHASE1 · COMPLETED · sponsor: **SynerGene Therapeutics, Inc.** · enrollment: 25 (actual)

## Conditions studied

- Neoplasm

## Interventions

- **GENETIC:** SGT-53

## Key facts

- **NCT ID:** NCT00470613
- **Lead sponsor:** SynerGene Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2017-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00470613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00470613, "Safety Study of Infusion of SGT-53 to Treat Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00470613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*